Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma

Kai Huang

doi:10.1002/cac2.12628

PDF

Cancer Communications ›› 2025, Vol. 45 ›› Issue (01) : 56-57. DOI: 10.1002/cac2.12628

RESEARCH HIGHLIGHTS

Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma

Kai Huang¹^,²

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Kai Huang. Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma. Cancer Communications, 2025, 45(01): 56‒57 https://doi.org/10.1002/cac2.12628

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol. 2022; 19(4): 269-280. CrossRef Google scholar

[2]	Dimitriou F, Cheng PF, Saltari A, Schaper-Gerhardt K. Staeger R, Haunerdinger V, et al. A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma. Nature Cancer. 2024; 5(9): 1390-1408. CrossRef Google scholar

[3]	Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM. Clinical and translational attributes of immune-related adverse events. Nat Cancer. 2024; 5(4): 557-571. CrossRef Google scholar

[4]	Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021; 184(3): 425-436. CrossRef Google scholar